<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Results of a Screening Program for Diagnosis of Amyloid Cardiomyopathy Among Patients with Left Ventricular Hypertrophy: PAPCAT Cardiac Amyloidosis Turkiye Survey

dc.contributor.authorOzpelit, Ebru
dc.contributor.authorCavusoglu, Yuksel
dc.contributor.authorGuler, Gamze Babur
dc.contributor.authorUnlu, Serkan
dc.contributor.authorYildirimturk, Ozlem
dc.contributor.authorYilmaz, Dilek Cicek
dc.contributor.authorOrem, Cihan
dc.contributor.authorBasarici, Ibrahim
dc.contributor.authorTufekcioglu, Omac
dc.contributor.authorTokgozoglu, Lale
dc.contributor.authorKarakulak, Ugur Nadir
dc.contributor.authorDincer, Irem
dc.contributor.authorKaya, Gamze Capa
dc.contributor.authorSivrioz, Ilknur Ak
dc.contributor.authorMurat, Selda
dc.contributor.authorGuler, Arda
dc.contributor.authorColak, Ayse
dc.contributor.authorSahin, Mursel
dc.contributor.authorKaplan, Elmas
dc.contributor.authorAkaslan, Dursun
dc.contributor.authorCabbar, Ayce Turer
dc.contributor.authorSunbul, Murat
dc.contributor.authorKaya, Yuksel
dc.contributor.authorZorkun, Cafer Sadik
dc.contributor.authorAgca, Fahriye Vatansever
dc.contributor.authorIkitimur, Baris
dc.contributor.authorOnbasili, Alper
dc.contributor.authorKilicgedik, Alev
dc.contributor.authorAltay, Hakan
dc.contributor.authorBuyukoner, Elif Eroglu
dc.contributor.authorDegertekin, Muzaffer
dc.date.accessioned2026-11-05T11:01:48Z
dc.date.issued2025
dc.description.abstractBackground: Cardiac amyloidosis (CA) is an increasingly recognized disease. Several recent advanced imaging techniques and parameters have been introduced into the diagnosis of CA. However, the first step in using those techniques is clinical suspicion. Left ventricular hypertrophy (LVH) is the main entity in rising the suspicion of CA in routine echocardiography, although it is not a diagnosisfor CA. The aim of this study isto investigate the prevalence of CA and its subtypes and predictive value of clinical and echocardiographic red flags of CA among consecutive adult patients with LVH identified during routine echocardiographic examination in 25 tertiary institutions in T & uuml;rkiye. Methods: This was a prospective observational multicenter, national registration study. Patients with LVH (interventricular septum thickness >= 13 mm or >15 mm in those with hypertension) were screened for CA stepwise. The first step was a clinical questionnaire for the red flags of CA. Those having >= 2 red flags were further analyzed by detailed echocardiography, blood tests, Tc-pyrophosphate (PYP) bone scintigraphy, and histopathological examination if needed. Parameters associated with CA were evaluated via univariate and multivariate analyses. Wild-type transthyretin (wTTR) vs. mutant-type TTR (mTTR), CA discriminators were also evaluated in the same manner. Results: A total of 420 patients meeting these criteria were included in the study. With a standardized algorithmic approach, 27.1% (114) of patients received a CA diagnosis. Among these patients with CA, 50.8% (58) were diagnosed with immunoglobulin free chain (AL) CA, 38.6% (44) with wTTR CA, and 7% (8) with mTTR CA. Leftventricular apical sparing pattern and restrictive type LV filling on echocardiography, low QRS voltage on ECG, bilateral carpal tunnel syndrome, low blood pressure, right ventricular diameter, and an increased basal heart rate (HR) were independent predictorsfor CA diagnosis. When it comesto diagnosis of wTTR CA; advanced age (age >75), lowertroponin values, absence of pericardial effusion and absence of proteinuria were the independent predictors. Conclusion: Cardiac amyloidosis is highly prevalent in a patient population with LVH and >2 red flagswho underwent a standardized algorithmic approach, in which apical sparing, restrictive filling pattern, low QRS voltage, carpal tunnel syndrome, low blood pressure, and increased HR are the highly suggestive signs of CA. Among this pool of newly diagnosed CA patients in T & uuml;rkiye, AL-CA constituted 50.8%, wTTR CA 38.6%, and mTTR CA 7%, emphasizing that approximately 1 in 2 patients diagnosed with CA may have TTR CA.
dc.description.issue10
dc.description.pages571-581
dc.description.volume29
dc.identifier.doi10.14744/AnatolJCardiol.2025.4942
dc.identifier.issn2149-2263
dc.identifier.issn2149-2271
dc.identifier.urihttps://doi.org/10.14744/AnatolJCardiol.2025.4942
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/10799
dc.identifier.wosWOS:001592862400009
dc.language.isoen
dc.publisherKARE PUBL
dc.relation.hasversion10.14744/AnatolJCardiol.2025.4942
dc.relation.ispartofANATOLIAN JOURNAL OF CARDIOLOGY
dc.subjectAmyloidosis
dc.subjectcardiac amyloidosis
dc.subjectleft ventricular hypertrophy
dc.subjecttransthyretin cardiac amyloidosis
dc.subjectCardiac & Cardiovascular Systems
dc.subjectCardiovascular System & Cardiology
dc.titleResults of a Screening Program for Diagnosis of Amyloid Cardiomyopathy Among Patients with Left Ventricular Hypertrophy: PAPCAT Cardiac Amyloidosis Turkiye Survey
dc.typeArticle
oaire.citation.editionScience Citation Index Expanded (SCI-EXPANDED)
oaire.citation.endPage581
oaire.citation.issue10
oaire.citation.startPage571
oaire.citation.volume29
person.identifier.orcid0000-0001-6179-8579
person.identifier.orcid0000-0001-8741-9610
person.identifier.ridAAA-3477-2020
person.identifier.ridA-9583-2008
person.identifier.ridAAE-1392-2021
person.identifier.ridAAA-6795-2020
person.identifier.ridAAE-4660-2020
person.identifier.ridABH-1463-2022
person.identifier.ridK-2361-2014
person.identifier.ridHJY-2884-2023
person.identifier.ridAAB-9237-2021
person.identifier.ridHKN-4198-2023
person.identifier.ridJWA-0879-2024
person.identifier.ridO-1466-2013
person.identifier.ridJKJ-2387-2023
person.identifier.ridAAL-2886-2021
person.identifier.ridQ-1247-2019
person.identifier.ridAAF-6919-2019
person.identifier.ridAAL-3760-2021

Files

Collections